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We describe a 2 ½ year old boy presenting with fever, abdominal pain and splinter haemorrhages of the
nails. On further examination there were signs of pneumonia with pleural effusion. This was treated with
mini-thoracotomy, drainage and intravenous antibiotics. Further diagnostic workup for underlying
causes showed diffuse cystic lung disease, suggestive of Langerhans cell histiocytosis. This was conﬁrmed
on pathology specimens, which showed Langerhans cells in lung tissue, nail bed and skin biopsy samples,
indicating multisystem Langerhans cell histiocytosis. The patient was treated with Prednisone and
Vinblastin according to the LCH-III guidelines. In this case report we give a brief description on cystic
lung disease in children, Langerhans cell histiocytosis and associated nail abnormalities.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Langerhans cell histiocytosis (LCH) is a rare disease characterized
by monoclonal proliferation of dendritic-cell related histiocytes
(Langerhans cells). These histiocytes have destructive behaviour for
the surrounding tissuewhich they inﬁltrate. Among the organs often
involved are the skeletal system, skin, thyroid gland and risk organs
like liver, lung, spleen and the haematopoietic system.
In this casewe present a young toddler primarily presenting with
signs of a complicated pneumonia, as the presenting sign of under-
lying systemic disease. Although lung involvement is frequently seen
in multisystem LCH, it is not often the presenting sign.
2. Patient presentation
A 2 ½ -year-old boy was referred to the paediatric outpatient
department for acute fever, abdominal pain, and decreased oral
intake. Furthermore, he had linear splinter haemorrhages of thesis; HRCT, High resolution
þ31 53 4872326.
-NC-ND license.nails for some weeks. Previous medical history was unremarkable
besides a recent tonsillectomy. Physical examination showed an ill
child with fever, tachypnoea (breathing rate 36/min), tachycardia
(heart rate 165/min) and oxygen saturation in room air between
89 and 93%. With oxygen supplementation via nasal cannula of
1 L/min, oxygen saturation was 97e98%. Blood pressure was
121/76 mmHg. On auscultation there was decreased air-entry over
the left hemithorax, pleural friction rub, and hepatomegaly. Labo-
ratory data revealed elevated C-reactive protein of 333 mg/l
(reference range <10 mg/l), erythrocyte sedimentation rate was
37 mm/h (reference range 3e13 mm/h), platelet count 573  109/l
(reference range 150e450  109/l), white blood cell count
24.6  109/l (reference range 4.0e10.0  109/l). Differential blood
count: neutrophils 86.6%, immature neutrophils 6%, lymphocytes
7.6%, monocytes 5.3%, eosinophils 0.3%, basophils 0.2%.
The chest radiograph revealed a basal consolidation in the left
lower lobe and opaciﬁcation along the lateral chest wall. Moreover,
there was some right-sided displacement of the heart and medi-
astinum. This was suspect of pulmonary consolidation with pleural
effusion. Additionally, the right lung and left upper lobe demon-
strated an evident reticulonodular pattern (Fig. 1).
The diagnosis of pneumonia with pleural effusion was made.
This was conﬁrmed with ultrasound. At this point the decision was
Fig. 1. Chest radiograph at presentation. Basal consolidation in the left lower lobe,
opaciﬁcation along the left lateral wall and mediastinal shift, indicating pneumonia
and pleural effusion. Reticulonodular pattern in right lung and left upper lobe.
Fig. 2. Chest radiograph, performed eight weeks after recovery, revealing persistent
reticulonodular pattern with features of honeycombing.
Fig. 3. High resolution CT. Diffuse bilateral cysts of varying size and wall thickness.
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with broad-spectrum antibiotics, amoxicillin-clavulanic acid and
gentamicin. Blood cultures remained negative. After initial
improvement, the patient deteriorated after four days with dysp-
noea and increased oxygen need. Chest ultrasound showed
increased pleural effusion and progressive organisation of the
effusion. Bacterial endocarditis was ruled out with negative blood
cultures and a normal cardiac ultrasound. A mini-thoracotomy was
performed with decortication of the left lung and placement of
a pleural drain. Pleural ﬂuid chemistry showed signs of pleural
exudate (pH 6.92, glucose <0.6 mmol/l, protein 35.7 g/L, lactate
dehydrogenase 2677 U/l)1 Antibiotics were switched to ﬂuclox-
acillin, gentamicin and clindamycin. Bacterial cultures of pleural
ﬂuid and blood remained negative. Afterwards, analysis of pleural
ﬂuid with polymerase chain reaction (16S-PCR) determined Strep-
tococcus pneumoniae as the causative pathogen. The patient fully
recovered within 10 days, had no oxygen need and was dismissed
from hospital care with oral antibiotics.
Since the chest radiograph showed not only pneumonia
and pleural effusion, but also interstitial abnormalities, a thorough
diagnostic workup was performed to rule out underlying causes of
pulmonary disease. The inﬂammatory markers had normalized.
Serological tests for viral, atypical and bacterial pathogens
were negative. Sweat test was negative. Tuberculin skin test was
negative.
The immunological survey was normal. The patient had been
vaccinated with a heptavalent pneumococcal conjugate vaccine
(PCV-7, Prevenar). There were normal pneumococcal antibody
levels. Subtyping of the pneumococcal strand was not possible,
since it was detected with 16S-PCR, not by culture.
Further imagingwas planned to be performed after full recovery
of the pleural empyema. Eight weeks after full recovery the chest
radiograph was still abnormal with a reticulonodular pattern and
features of honeycombing (Fig. 2). Therefore, a high resolution
Computed Tomography (HRCT) was performed. The HRCT of the
thorax revealed numerous bilateral cysts of different size andvarying wall thickness (Fig. 3). There were no signs of emphysema
or bronchiectasis. Hence, Langerhans cell histiocytosis (LCH) was
suspected.
Further diagnostic testing was performed to conﬁrm the diag-
nosis. Abdominal ultrasound was normal, with no signs of hepatic
involvement or hepatomegaly and normal liver function tests.
The initial presentation with hepatomegaly had been caused by
diagfragmatic ﬂattening due to pulmonary hyperinﬂation.
Full body X-ray series showed no osteolytic lesions indicative for
LCH. Under general anaesthesia an open lung biopsy, skin biopsy,
nail bed biopsy, bone biopsy and bone marrow aspiration was
performed.
The lung biopsy showed foci of histiocytes, mixed with eosin-
ophilic granulocytes, with a stellar distribution. In these foci cysts
were developing. CD1a staining was highly positive and S100
staining mildly positive, indicative of Langerhans Cell Histiocytosis.
Skin- and nail bed specimens also showed presence of CD1a-
positive cells. Bone marrow aspiration was negative.
The patient was treated following the LCH-III protocol (Histio-
cyte Society) with Vinblastin and Prednison. After six weeks, the
patient responded well to chemotherapy at the ﬁrst course evalu-
ation. Nail and skin abnormalities improved, and chest CT remained
stable. Bronchoalveolair lavage at 12 weeks treatment showed less
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biopsy showed no signs of active histiocytosis. The clinical course
was complicated by recurrent pneumothoraces of the right lung
due to spontaneous cyst rupture, which were primarily treated
with pleural drainage and ﬁnally with pleurodesis. Since the initial
pneumonia/empyema was treated with a thoracotomy and decor-
tication, the left lung was probably sufﬁciently protected against
recurrent pneumothoraces.
The further course was uneventful under continuous treatment
with vincristine, cytarabine and prednisolon. There are minimal
signs of histiocytosis activity in the skin and radiological exami-
nations of the lung did not show any progression. The child is in
excellent condition, and we are currently tapering the medication.
3. Discussion
3.1. Cystic lung disease
HRCT showed extensive pulmonary damage with numerous
cysts. In cystic lung disease one should differentiate between cysts
or cavities. The distribution can be focal, multifocal or diffuse. In
adults, causes of diffuse cystic lung disease include end stage
idiopathic pulmonary ﬁbrosis, connective tissue disease-related
pulmonary ﬁbrosis, asbestosis, advanced sarcoidosis or metastatic
disease. However, all these disease are very rare in children. Diffuse
cystic lung disease in children can be caused by lymphangioleio-
myomatosis and LCH.2,3 Lymphangioleiomyomatosis has been
described in adolescents and young adults, but is mainly described
in smoking females and not in children. The diagnostic imaging in
a child is suggestive for the diagnosis of LCH.
The most common early radiological ﬁnding in pulmonary LCH
is a reticulonodular pattern, due to granulomatous nodules con-
taining Langerhans histiocytes and eosinophils in the wall of
bronchioles. Later, granulomas are replaced by ﬁbrosis and the
formation of thin-walled air-ﬁlled cysts.4
3.2. Langerhans cell histiocytosis
Langerhans cell histiocytosis is a class I histiocytosis syndrome
of dendritic origin. It is rare disorder characterized by monoclonal
proliferation of dendritic-cell related histiocytes (Langerhans cells),
with a variable admixture of other cells, which form granulomas
with proliferative and locally destructive behaviour. These histio-
cytes can cause subsequent inﬁltration of various organs.5e8 LCH is
considered a clonal proliferation of Langerhans cells as a reactive,
rather than a malignant process.7e9
Most often children are affected, with a peak incidence of
0.2e1.0/100.000 children per year from 1 to 4 years of age.7,10e12
According to the number of different organs involved, single
system and multisystem disease are distinguished.5,7,9e11 LCH
predominantly affects the skeletal system and skin, although
central nerve system, thyroid and the so-called risk organs (liver,
spleen and haematopoietic system) may also be affected.
In children, lung involvement is present in about 15% of all
patients and in 24% of patients with multisystem disease.13
Pulmonary involvement is rarely the most predominant clinical
manifestation.4,6 Of the patients with multisystem LCH without
pulmonary abnormalities, 8.8% develop pulmonary LCH within the
next year.13 Isolated pulmonary LCH occurs in only 1% of the
cases.14e16 In adults, pulmonary histiocytosis is closely related to
smoking.17
Clinical presentation of symptomatic lung involvement in LCH
in children is nonspeciﬁc, such as dyspnoea, cough, chest pain,
fatigue, wheezing, and tachypnoea.4,5 When cysts are situated in
the periphery of the lung, the patient is at risk for cysts rupturewhich could cause a pneumothorax, as has been the case in our
patient.4,14
To obtain deﬁnite diagnosis, immunohistochemical demon-
stration of CD1a epitopes on the cell surface and/or demonstration
of Birbeck granules in the cytoplasm by electron microscopy is
required, in addition to conventional light microscopy (and positive
staining for S100-protein). Once LCH is diagnosed, based on typical
histopathological ﬁndings, stratiﬁcation into single-system or
multisystem disease is based on the number of organs involved.
Patients with localized disease have a good prognosis and may
not require any treatment.18e20 On the other hand, for multisystem
LCH, the Histiocyte Society recommends an intensive treatment
during the ﬁrst 6 weeks of therapy and continuation treatment
thereafter.
In children, prognosis mainly depends on two negative prog-
nostic factors: risk organ involvement (dysfunction of liver, spleen
and haematopoietic system), and poor response to initial treat-
ment.7,11,18e20 Involvement of risk organs is associated with
a signiﬁcantly increased mortality rate.7,19,20 Patients with risk
organ involvement who do not achieve a response to initial treat-
ment have a 75% risk of fatal outcome.19 In contrast, those who do
respond to initial chemotherapy have an 88%e91% survival rate.19,21
Several studies and clinical observations have concluded that, in
paediatric patients, lung involvement is the only risk organ that is
not associated with increased mortality.6,15 This was recently
conﬁrmed in a large retrospective study of 420 patients with
multisystem LCH, in which pulmonary involvement did not alter 5-
year survival rate.13 Lung involvement will therefore no longer be
seen as a risk organ.15
An age younger than 2 years at diagnosis was thought to be
related to a potentially fatal outcome, although recent studies show
that an unfavourable outcome is only related to those young chil-
drenwith a multisystem disease. Young age itself is no longer a risk
factor for mortality.19
Permanent lung damage after pulmonary LCH in children is
relatively uncommon, incidence ranging from 1 up to 33%.22,23
However, considering the severe pulmonary abnormalities and
recurring pneumothoraces in our patient, permanent damage and
long term sequelae are very likely.
3.3. Nail abnormalities
Nail involvement in LCH is uncommon, and usually occurs in
patients with multisystem disease and involvement of risk organs,
therefore it is stated to be an unfavourable prognostic sign. The nail
involvement may include subungual hyperkeratosis, purpuric
striae and longitudinal grooving, onycholysis and loss of the nail
plate (Fig. 4). Previous case reports have mostly reported destruc-
tive nail changes.20,24
3.3.1. What this paper adds to the literature
In this case we have been able to illustrate the remarkable
pulmonary abnormalities caused by pulmonary manifestation of
Langerhans cell histiocytosis in a young child. We have described
the differential diagnosis of diffuse cystic lung disease in children.
Also, both skin and nail abnormalities can be the presenting signs of
LCH, but are often missed on initial presentation.
3.4. Summary
This case report describes a young child presenting with
pneumonia, pleural effusion and nail abnormalities as the ﬁrst
presenting signs of Langerhans Cell histiocytosis. In this case, the
histiocytosis was limited to the skin, nails and lungs. Although lung
involvement develops in approximately half of the multisystem
Fig. 4. Detailed photograph of the nails of the patient, showing onchyolysis (a) and
splinter hemmorhages (b) of the nails.
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usually does not predominate. The nail abnormalities are consistent
with LCH, although uncommon.
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